FDA addresses biopharma's diversity problem with new draft guidance
Back in 2020 — as drugmakers struggled to enroll diverse populations in Covid-19 trials — the FDA released new guidance urging pharma companies to devise a plan …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
